lansoprazole and Esophagitis studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.

Research Excerpts

Excerpt	Relevance	Reference
" lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis."	10.20	Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003)
"Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks."	9.69	Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. ( DeVault, K; Hunt, B; Katz, P; Laine, L; Lowe, J; Mitev, S; Spechler, S, 2023)
" The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole."	9.69	Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. ( Akiyama, J; Aoyama, N; Haruma, K; Kanoo, T; Kinoshita, Y; Kushima, R; Kusumoto, N; Miyata, K; Uemura, N; Yao, T, 2023)
"Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double-blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days."	9.30	Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. ( Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J, 2019)
" lansoprazole in patients with erosive oesophagitis (EE), and to establish its long-term safety and efficacy as maintenance therapy."	9.22	Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2016)
"Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment."	9.17	Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013)
"In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year."	9.14	Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. ( Atkinson, S; Freston, JW; Haber, MM; Hunt, B; Kovacs, TO; Peura, DA, 2009)
"Dexlansoprazole MR heals all grades of erosive oesophagitis (EO)."	9.14	Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. ( Atkinson, SN; Howden, CW; Larsen, L; Metz, DC; O'Neil, J; Perez, MC, 2009)
"To assess the efficacy and safety of dexlansoprazole MR in healing erosive oesophagitis (EO)."	9.14	Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. ( Atkinson, SN; Lee, M; Perez, MC; Peura, D; Pilmer, BL; Shaheen, NJ; Sharma, P, 2009)
"The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials."	9.14	The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2009)
"Changes in gastric histology associated with long-term maintenance therapy with lansoprazole for erosive oesophagitis have not been well described."	9.14	Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2010)
"Dexlansoprazole MR, a modified-release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis."	9.14	Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. ( Atkinson, SN; Howden, CW; Larsen, LM; Palmer, R; Perez, MC, 2009)
"To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 13 and 24 months of age with gastroesophageal reflux disease (GERD)."	9.12	Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ( Amer, F; Chiu, YL; Heyman, MB; Huang, B; Winter, HS; Zhang, W, 2007)
"To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients."	9.11	Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. ( Chiu, YL; Kovacs, TO; Lee, CQ; Metz, DC; Pilmer, BL, 2004)
"Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7."	9.11	Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005)
"To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age."	9.10	Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002)
"To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists."	9.09	Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000)
"This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis."	9.09	Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001)
"Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux."	9.08	Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998)
"After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded."	9.08	Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997)
"Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks."	9.08	Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996)
"Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily."	9.07	An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993)
"Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease."	8.87	Dexlansoprazole MR for the management of gastroesophageal reflux disease. ( Behm, BW; Peura, DA, 2011)
"To describe the pharmacology, pharmacokinetics, and efficacy of dexlansoprazole in the treatment of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) and healing and maintenance of healing of all grades of erosive esophagitis (EE)."	8.86	Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. ( Abel, C; Desilets, AR; Willett, K, 2010)
"Dexlansoprazole modified release (dexlansoprazole MR) is an orally administered delayed-release formulation of the R-enantiomer of the proton pump inhibitor lansoprazole that is effective in improving the healing of all grades of erosive oesophagitis, maintaining the healing of erosive oesophagitis and in the treatment of symptomatic non-erosive reflux disease (NERD)."	8.86	Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. ( Croxtall, JD; Scott, LJ, 2010)
"An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole."	8.82	Intravenous lansoprazole: in erosive oesophagitis. ( Dando, TM; Plosker, GL, 2004)
"Omeprazole and lansoprazole are used to treat erosive oesophagitis in the respective daily doses of 20 and 30 mg."	8.81	Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. ( Howden, CW; Leontiadis, GI; Sharma, VK, 2001)
" In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment."	7.79	The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013)
"We performed a retrospective analysis of data from 287 Helicobacter pylori-negative erosive esophagitis (EE) patients healed after 4 or 8 weeks of therapy with dexlansoprazole modified release (MR) or lansoprazole, and then randomized to placebo in 6-month maintenance trials."	7.77	Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. ( Han, C; Metz, DC; Perez, MC; Pilmer, BL, 2011)
"Heartburn was controlled on lansoprazole 30 mg/per day in 76."	7.72	Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003)
"Based on limited number of published non-inferiority RCTs, our analysis demonstrates that among patients with EE, vonoprazan 20 mg once-daily dosing achieves comparable and in those with severe EE, higher endoscopic healing rates as compared to lansoprazole 30 mg once-daily dosing."	7.01	Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. ( Adler, DG; Bapaye, J; Chandan, OC; Chandan, S; Deliwala, S; Dhindsa, B; Facciorusso, A; Kassab, LL; Mohan, BP; Ramai, D, 2023)
" Safety for all study participants was monitored by adverse event reports and laboratory evaluations."	6.70	Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002)
"Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials."	6.41	Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002)
" lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis."	6.20	Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003)
"Adults with erosive esophagitis were randomized to once-daily vonoprazan, 20 mg, or lansoprazole, 30 mg, for up to 8 weeks."	5.69	Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. ( DeVault, K; Hunt, B; Katz, P; Laine, L; Lowe, J; Mitev, S; Spechler, S, 2023)
" The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole."	5.69	Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. ( Akiyama, J; Aoyama, N; Haruma, K; Kanoo, T; Kinoshita, Y; Kushima, R; Kusumoto, N; Miyata, K; Uemura, N; Yao, T, 2023)
"This study aimed to explore the non-inferior efficacy and safety of keverprazan to lansoprazole in treating erosive oesophagitis (EO)."	5.51	The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. ( Chen, H; Chen, M; Chen, S; Guo, Q; Li, F; Li, S; Li, X; Liao, A; Liu, C; Liu, D; Miao, X; Wang, Y; Wen, Z; Xia, M; Xiao, Y; Xu, M; Yin, H; Zhang, Y, 2022)
"The prospective, open-label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD)."	5.34	Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. ( Chang, TE; Hou, MC; Huang, YH; Lee, FY; Lin, XH; Luo, JC; Ting, PH, 2020)
"Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double-blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days."	5.30	Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. ( Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J, 2019)
" lansoprazole in patients with erosive oesophagitis (EE), and to establish its long-term safety and efficacy as maintenance therapy."	5.22	Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2016)
"Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment."	5.17	Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013)
"Dexlansoprazole MR 30 mg once daily (QD) is approved in adults for the treatment of symptomatic nonerosive gastroesophageal reflux disease (GERD) and maintenance of healed erosive esophagitis (EE); 60 mg is approved for healing EE."	5.16	Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. ( Kukulka, M; Perez, MC; Wu, J, 2012)
"Dexlansoprazole MR heals all grades of erosive oesophagitis (EO)."	5.14	Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. ( Atkinson, SN; Howden, CW; Larsen, L; Metz, DC; O'Neil, J; Perez, MC, 2009)
"The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials."	5.14	The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2009)
"Dexlansoprazole MR, a modified-release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis."	5.14	Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. ( Atkinson, SN; Howden, CW; Larsen, LM; Palmer, R; Perez, MC, 2009)
"Changes in gastric histology associated with long-term maintenance therapy with lansoprazole for erosive oesophagitis have not been well described."	5.14	Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2010)
"A total of 320 patients over 65 years with endoscopically diagnosed esophagitis were randomly assigned to one of the following treatments for 8 wk: (1) omeprazole 20 mg/d; (2) lansoprazole 30 mg/d; (3) pantoprazole 40 mg/d, or (4) rabeprazole 20 mg/d."	5.12	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. ( Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D, 2007)
"To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 13 and 24 months of age with gastroesophageal reflux disease (GERD)."	5.12	Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ( Amer, F; Chiu, YL; Heyman, MB; Huang, B; Winter, HS; Zhang, W, 2007)
"To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients."	5.11	Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. ( Chiu, YL; Kovacs, TO; Lee, CQ; Metz, DC; Pilmer, BL, 2004)
"Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7."	5.11	Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005)
"To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age."	5.10	Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002)
"To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists."	5.09	Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000)
"This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis."	5.09	Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001)
"Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks."	5.08	Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996)
"After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded."	5.08	Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997)
"Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux."	5.08	Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998)
"Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily."	5.07	An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993)
"Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease."	4.87	Dexlansoprazole MR for the management of gastroesophageal reflux disease. ( Behm, BW; Peura, DA, 2011)
"Dexlansoprazole modified release (dexlansoprazole MR) is an orally administered delayed-release formulation of the R-enantiomer of the proton pump inhibitor lansoprazole that is effective in improving the healing of all grades of erosive oesophagitis, maintaining the healing of erosive oesophagitis and in the treatment of symptomatic non-erosive reflux disease (NERD)."	4.86	Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. ( Croxtall, JD; Scott, LJ, 2010)
"An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole."	4.82	Intravenous lansoprazole: in erosive oesophagitis. ( Dando, TM; Plosker, GL, 2004)
"To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e."	4.79	Lansoprazole: a proton pump inhibitor. ( Garnett, WR, 1996)
" The dose of lansoprazole needed to heal the esophagitis was not significantly associated with the risk for clinical relapse (hazard ratio [HR] 1."	3.80	High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. ( Brito, HS; Kawakami, E; Machado, RS; Ogata, SK; Yamamoto, E, 2014)
" In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment."	3.79	The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013)
"We performed a retrospective analysis of data from 287 Helicobacter pylori-negative erosive esophagitis (EE) patients healed after 4 or 8 weeks of therapy with dexlansoprazole modified release (MR) or lansoprazole, and then randomized to placebo in 6-month maintenance trials."	3.77	Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. ( Han, C; Metz, DC; Perez, MC; Pilmer, BL, 2011)
" pylori-negative subjects with erosive esophagitis (>or= grade 2; n=196), nonerosive reflux disease (n=688), or functional dyspepsia (n=711) who participated in US Takeda-sponsored lansoprazole trials."	3.76	Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. ( Atkinson, S; Haber, MM; Hunt, B; Peura, DA, 2010)
" The aim of this study was to investigate the relationship between the severity of reflux esophagitis and esophageal dysmotility and evaluate the effect of prolonged treatment with proton pump inhibitor (lansoprazole 30 mg/day) on esophageal motility in patients with severe reflux esophagitis associated with esophageal motility disorder."	3.74	Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. ( Hou, XH; Song, GQ; Xie, XP; Xu, JY, 2007)
"Heartburn was controlled on lansoprazole 30 mg/per day in 76."	3.72	Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003)
"This retrospective analysis evaluated data collected in a randomized, double-blind clinical trial that assessed the efficacy and safety of once-daily esomeprazole 40 mg (n = 2,624) versus lansoprazole 30 mg (n = 2,617) for up to 8 wk in the treatment of reflux-associated erosive esophagitis."	3.72	Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. ( Levine, D; Traxler, BM; Vakil, NB, 2004)
"Based on limited number of published non-inferiority RCTs, our analysis demonstrates that among patients with EE, vonoprazan 20 mg once-daily dosing achieves comparable and in those with severe EE, higher endoscopic healing rates as compared to lansoprazole 30 mg once-daily dosing."	3.01	Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. ( Adler, DG; Bapaye, J; Chandan, OC; Chandan, S; Deliwala, S; Dhindsa, B; Facciorusso, A; Kassab, LL; Mohan, BP; Ramai, D, 2023)
" Safety for all study participants was monitored by adverse event reports and laboratory evaluations."	2.70	Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002)
"Posttreatment clarithromycin resistance is common in patients who do not experience success with therapy."	2.68	Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. ( Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS, 1996)
"Dexlansoprazole was well tolerated compared with placebo or lansoprazole in all studies."	2.46	Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system. ( Emerson, CR; Marzella, N, 2010)
"Esomeprazole 40 mg was found to provide significantly higher healing rates at 4 weeks [OR 1."	2.45	Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. ( DAS, R; Edwards, SJ; Lind, T; Lundell, L, 2009)
"To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects."	2.43	Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006)
"It has been shown that GERD has a significant impact on patients' quality of life; therefore, improvement of quality of life is one of the major goals of GERD treatment."	2.42	The impact of gastroesophageal reflux disease on quality of life. ( Kamolz, T; Pointner, R; Velanovich, V, 2003)
"Food and Drug Administration for treatment of gastroesophageal reflux disease: radiofrequency energy delivery to the gastroesophageal junction, and transoral flexible endoscopic suturing."	2.41	Gastroesophageal reflux disease: new treatments. ( Katz, PO, 2002)
"Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells."	2.41	An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002)
"Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials."	2.41	Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002)
"Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion."	2.40	Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997)
"Reflux esophagitis is a chronic condition and after stopping antisecretory treatment, including lansoprazole, most patients relapse in terms of symptoms and endoscopical lesions, which suggests the need for long-term treatment."	2.38	Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. ( Di Fede, F; Dobrilla, G, 1993)
" A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events."	1.35	Long-term proton pump inhibitor use in children: a retrospective review of safety. ( Boyer, K; Tolia, V, 2008)
"Forty-five patients with suspected gastroesophageal reflux diseases related symptoms (sore throat, throat burning, throat clearing, globus sensation, cough, halitozis, dysphonia, dysphagia, postnasal dripping, vocal fatigue, and sputum) were included in this study."	1.35	Association of laryngopharyngeal manifestations and gastroesophageal reflux. ( Akkaynak, C; Naiboglu, B; Ozel, L; Toros, AB; Toros, SZ; Yüksel, OD, 2009)
"Cough was significantly less severe in NEE adolescents than in younger children."	1.33	Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006)
"Lansoprazole 30 mg was started."	1.33	Pill esophagitis caused by telithromycin: a case report. ( Büyükberber, M; Demirci, F; Gülşen, MT; Kis, C; Koruk, M; Savaş, MC, 2006)
"In refractory cases of GERD, eosinophilic esophagitis must be considered before any surgical measure."	1.32	Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice. ( Cury, EK; Faintuch, S; Schraibman, V, 2004)

Research

Studies (77)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Healing Phase: Percentage of 24-hour Heartburn-free Days

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	12 (15.58)	18.2507
2000's	39 (50.65)	29.6817
2010's	21 (27.27)	24.3611
2020's	5 (6.49)	2.80

Authors	Studies
Chen, S	1
Liu, D	1
Chen, H	2
Liao, A	1
Li, F	1
Liu, C	1
Li, X	1
Li, S	1
Zhang, Y	1
Wang, Y	1
Xia, M	1
Guo, Q	1
Miao, X	1
Wen, Z	1
Xu, M	1
Yin, H	1
Chen, M	1
Xiao, Y	1
Laine, L	1
DeVault, K	1
Katz, P	1
Mitev, S	1
Lowe, J	1
Hunt, B	8
Spechler, S	1
Haruma, K	1
Kinoshita, Y	1
Yao, T	1
Kushima, R	1
Akiyama, J	1
Aoyama, N	1
Kanoo, T	1
Miyata, K	1
Kusumoto, N	1
Uemura, N	1
Chandan, S	1
Deliwala, S	1
Mohan, BP	1
Ramai, D	1
Dhindsa, B	1
Bapaye, J	1
Kassab, LL	1
Chandan, OC	1
Facciorusso, A	1
Adler, DG	1
Lin, XH	1
Luo, JC	1
Ting, PH	1
Chang, TE	1
Huang, YH	1
Hou, MC	1
Lee, FY	1
Oshima, T	1
Arai, E	1
Taki, M	1
Kondo, T	1
Tomita, T	1
Fukui, H	1
Watari, J	1
Miwa, H	1
Peura, DA	8
Pilmer, B	3
Mody, R	2
Perez, MC	7
Yamamoto, E	1
Brito, HS	1
Ogata, SK	1
Machado, RS	1
Kawakami, E	1
Ashida, K	2
Sakurai, Y	2
Nishimura, A	2
Kudou, K	2
Hiramatsu, N	2
Umegaki, E	2
Iwakiri, K	2
Chiba, T	1
Ueta, E	1
Fujikawa, T	1
Imagawa, A	1
Hori, T	1
Toros, SZ	1
Toros, AB	1
Yüksel, OD	1
Ozel, L	1
Akkaynak, C	1
Naiboglu, B	1
Freston, JW	5
Haber, MM	5
Kovacs, TO	6
Atkinson, S	5
Sharma, P	1
Shaheen, NJ	1
Pilmer, BL	3
Lee, M	1
Atkinson, SN	3
Peura, D	1
Metz, DC	3
Howden, CW	3
Larsen, L	1
O'Neil, J	1
Hisada, M	2
Edwards, SJ	1
Lind, T	1
Lundell, L	1
DAS, R	1
Larsen, LM	1
Palmer, R	1
González F, CG	1
Torres, J	1
Molina U, R	1
Harris, PR	1
Yaghoobi, M	1
Padol, S	1
Yuan, Y	1
Hunt, RH	1
Abel, C	1
Desilets, AR	1
Willett, K	1
Davies, SL	1
Dohil, R	1
Newbury, R	1
Fox, L	1
Bastian, J	1
Aceves, S	1
Croxtall, JD	1
Scott, LJ	1
Emerson, CR	1
Marzella, N	1
Juul-Hansen, P	1
Rydning, A	1
Hershcovici, T	1
Jha, LK	1
Fass, R	1
Kukulka, M	1
Wu, J	1
Behm, BW	1
Han, C	1
Katz, PO	2
Lauritsen, K	1
Devière, J	1
Bigard, MA	1
Bayerdörffer, E	1
Mózsik, G	1
Murray, F	1
Kristjánsdóttir, S	1
Savarino, V	1
Vetvik, K	1
De Freitas, D	1
Orive, V	1
Rodrigo, L	1
Fried, M	1
Morris, J	1
Schneider, H	1
Eklund, S	1
Larkö, A	1
Tolia, V	3
Fitzgerald, J	1
Hassall, E	2
Huang, B	5
Kane, R	1
Ferry, G	1
Gunasekaran, T	1
Keith, R	1
Book, L	1
Kamolz, T	1
Pointner, R	1
Velanovich, V	1
Abu Farsakh, N	1
Cury, EK	1
Schraibman, V	1
Faintuch, S	1
Vakil, NB	1
Traxler, BM	1
Levine, D	1
Dando, TM	1
Plosker, GL	1
Lee, CQ	1
Chiu, YL	3
Hirschowitz, BI	1
Simmons, J	1
Mohnen, J	1
Fossmark, R	1
Johnsen, G	1
Johanessen, E	1
Waldum, HL	1
Rahhal, RM	1
Ramkumar, DP	1
Pashankar, DS	1
Gupta, SK	1
Amer, F	2
Heyman, MB	2
Büyükberber, M	1
Demirci, F	1
Savaş, MC	1
Kis, C	1
Gülşen, MT	1
Koruk, M	1
Guimarães, EV	1
Marguet, C	1
Camargos, PA	1
Zhang, W	1
Winter, HS	1
Kawamura, M	1
Ohara, S	1
Koike, T	1
Iijima, K	1
Suzuki, H	1
Kayaba, S	1
Noguchi, K	1
Abe, S	1
Noguchi, M	1
Shimosegawa, T	1
Xu, JY	1
Xie, XP	1
Song, GQ	1
Hou, XH	1
Boyer, K	1
Pilotto, A	1
Franceschi, M	1
Leandro, G	1
Scarcelli, C	1
D'Ambrosio, LP	1
Paris, F	1
Annese, V	1
Seripa, D	1
Andriulli, A	1
Di Mario, F	1
Dam, C	1
Bygum, A	1
Dobrilla, G	1
Di Fede, F	1
Brunner, G	1
Arnold, R	1
Hennig, U	1
Fuchs, W	1
Mee, AS	1
Rowley, JL	1
Garnett, WR	1
Langtry, HD	1
Wilde, MI	1
Moayyedi, P	1
Langworthy, H	1
Shanahan, K	1
Tompkins, DS	1
Dixon, MF	1
Chalmers, DM	1
Axon, AT	1
Franko, TG	1
Richter, JE	2
Hatlebakk, JG	1
Berstad, A	1
Janczewska, I	1
Sagar, M	1
Sjöstedt, S	1
Hammarlund, B	1
Iwarzon, M	1
Seensalu, R	1
Cockayne, SE	1
Glet, RJ	1
Gawkrodger, DJ	1
McDonagh, AJ	1
Feldman, M	1
Cryer, B	1
Sammer, D	1
Lee, E	1
Spechler, SJ	1
Franco, MT	1
Salvia, G	1
Terrin, G	1
Spadaro, R	1
De Rosa, I	1
Iula, VD	1
Cucchiara, S	1
Sharma, VK	1
Leontiadis, GI	1
Geboes, K	1
Dekker, W	1
Mulder, CJ	1
Nusteling, K	1
Kahrilas, PJ	1
Sontag, SJ	1
Pencyla, JL	1
Maekawa, T	1
Ohji, G	1
Inoue, R	1
Shimoyama, M	1
Shimada, T	1
Misaki, F	1
Hinder, RA	1
Bown, RL	1
Jackson, RL	1
Ballard, ED	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients With Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan[NCT04124926]	Phase 3	1,027 participants (Actual)	Interventional	2019-10-28	Completed
Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393]	Phase 4	200 participants (Anticipated)	Interventional	2015-10-31	Enrolling by invitation
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251719]	Phase 3	2,054 participants (Actual)	Interventional	2005-12-31	Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)[NCT00321984]	Phase 3	947 participants (Actual)	Interventional	2006-06-30	Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251693]	Phase 3	2,038 participants (Actual)	Interventional	2005-12-31	Completed
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466]	Phase 4	82 participants (Actual)	Interventional	2019-05-26	Terminated (stopped due to Budget for the study was withdrawn and discontinued)
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.[NCT00321737]	Phase 3	445 participants (Actual)	Interventional	2006-05-31	Completed
A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753]	Phase 4	143 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis[NCT00255151]	Phase 3	451 participants (Actual)	Interventional	2006-01-31	Completed
A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis[NCT00255164]	Phase 3	451 participants (Actual)	Interventional	2006-01-31	Completed
Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis[NCT03781596]	Phase 4	100 participants (Anticipated)	Interventional	2018-10-02	Recruiting
Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial[NCT00638456]	Phase 2	32 participants (Actual)	Interventional	2008-02-29	Completed
Prospective Pilot Study Evaluating the Efficacy of Low-Dose Topical Steroids in Maintaining Histologic Remission of Eosinophilic Esophagitis in Children[NCT05309590]		50 participants (Anticipated)	Observational [Patient Registry]	2014-05-31	Active, not recruiting
Phenotypic Characterization of Pediatric Patients With Esophageal Eosinophilia and Biomarkers Investigation for the Diagnosis of Eosinophilic Esophagitis[NCT03069573]		110 participants (Actual)	Observational [Patient Registry]	2015-01-01	Completed
A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children[NCT01458418]		4 participants (Actual)	Interventional	2011-12-31	Terminated (stopped due to Inability to complete enrollment due to difficulty in finding subjects)
A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease[NCT00847210]	Phase 1	36 participants (Actual)	Interventional	2009-05-31	Completed
An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan[NCT03079050]	Phase 4	33 participants (Actual)	Interventional	2017-02-27	Completed
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373]	Phase 4	72 participants (Actual)	Interventional	2003-03-31	Completed
A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188]	Phase 1	24 participants (Actual)	Interventional	2021-06-24	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase. (NCT04124926)
Timeframe: Day 1 to Week 8

Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2

Intervention	percentage of days (Mean)
Healing Phase: Vonoprazan 20 mg	66.8
Healing Phase: Lansoprazole 30 mg	64.1

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. (NCT04124926)
Timeframe: Week 2

Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8

Intervention	percentage of participants (Number)
Healing Phase: Vonoprazan 20 mg	74.3
Healing Phase: Lansoprazole 30 mg	68.2

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. (NCT04124926)
Timeframe: Week 8

Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2

Intervention	percentage of participants (Number)
Healing Phase: Vonoprazan 20 mg	92.9
Healing Phase: Lansoprazole 30 mg	84.6

"A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.~LA Classification of Esophagitis Grading Scale:~Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.~Grade D: One or more mucosal breaks, which involves at least 75% of the circumference." (NCT04124926)
Timeframe: Week 2

Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8

Intervention	percentage of participants (Number)
Healing Phase: Vonoprazan 20 mg	70.2
Healing Phase: Lansoprazole 30 mg	52.6

Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3

Intervention	percentage of participants (Number)
Healing Phase: Vonoprazan 20 mg	91.7
Healing Phase: Lansoprazole 30 mg	72.0

Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3. (NCT04124926)
Timeframe: Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment)

Maintenance Phase: Percentage of 24-hour Heartburn-free Days

Intervention	percentage of participants (Number)
Healing Phase: Vonoprazan 20 mg	34.4
Healing Phase: Lansoprazole 30 mg	32.2

Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24

Intervention	percentage of days (Mean)
Maintenance Phase: Vonoprazan 10 mg	80.9
Maintenance Phase: Vonoprazan 20 mg	80.6
Maintenance Phase: Lansoprazole 15 mg	78.6

A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. (NCT04124926)
Timeframe: Week 24

Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24

Intervention	percentage of participants (Number)
Maintenance Phase: Vonoprazan 10 mg	79.2
Maintenance Phase: Vonoprazan 20 mg	80.7
Maintenance Phase: Lansoprazole 15 mg	72.0

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	percentage of participants (Number)
Maintenance Phase: Vonoprazan 10 mg	74.7
Maintenance Phase: Vonoprazan 20 mg	77.2
Maintenance Phase: Lansoprazole 15 mg	61.5

Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: Week 8

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	77.8
Dexlansoprazole MR 90 mg QD	86.3
Lansoprazole 30 mg QD	78.9

Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	87.6
Dexlansoprazole MR 90 mg QD	93.3
Lansoprazole 30 mg QD	87.7

Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	69.7
Dexlansoprazole MR 90 mg QD	70.6
Lansoprazole 30 mg QD	65.4

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	80.1
Dexlansoprazole MR 90 mg QD	80.4
Lansoprazole 30 mg QD	77.0

Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	86.9
Dexlansoprazole MR 90 mg QD	89.4
Lansoprazole 30 mg QD	84.6

Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	93.1
Dexlansoprazole MR 90 mg QD	94.9
Lansoprazole 30 mg QD	91.5

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks

Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median

Intervention	percentage of days (Mean)
Placebo QD	25.0
Dexlansoprazole MR 30 mg QD	50.3
Dexlansoprazole MR 60 mg QD	49.1

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks

Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean

Intervention	percentage of days (Median)
Placebo QD	18.5
Dexlansoprazole MR 30 mg QD	54.9
Dexlansoprazole MR 60 mg QD	50.0

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks

Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median

Intervention	percentage of days (Mean)
Placebo QD	47.1
Dexlansoprazole MR 30 mg QD	67.6
Dexlansoprazole MR 60 mg QD	65.0

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	percentage of days (Median)
Placebo QD	51.7
Dexlansoprazole MR 30 mg QD	80.8
Dexlansoprazole MR 60 mg QD	76.9

Percentage of subjects with baseline EE grade C or D combined who have complete healing of erosive esophagitis as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	79.7
Dexlansoprazole MR 90 mg QD	74.1
Lansoprazole 30 mg QD	65.0

Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	88.9
Dexlansoprazole MR 90 mg QD	83.8
Lansoprazole 30 mg QD	74.5

Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analyses.

Intervention	Percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	85.3
Dexlansoprazole MR 90 mg QD	85.8
Lansoprazole 30 mg QD	79.0

Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method.

Intervention	Percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	66.2
Dexlansoprazole MR 90 mg QD	68.8
Lansoprazole 30 mg QD	64.8

Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.

Intervention	Percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	77.0
Dexlansoprazole MR 90 mg QD	78.8
Lansoprazole 30 mg QD	76.5

Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 weeks

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.

Intervention	Percentage of subjects (Number)
Dexlansoprazole MR 60 mg QD	92.3
Dexlansoprazole MR 90 mg QD	92.2
Lansoprazole 30 mg QD	86.1

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321737)
Timeframe: 6 months

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.

Intervention	Percentage of Days (Mean)
Placebo QD	36.0
Dexlansoprazole MR 30 mg QD	83.3
Dexlansoprazole MR 60 mg QD	78.4

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00321737)
Timeframe: 6 months

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.

Intervention	Percentage of Days (Median)
Placebo QD	28.6
Dexlansoprazole MR 30 mg QD	96.1
Dexlansoprazole MR 60 mg QD	90.9

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.

Intervention	Percentage of Days (Mean)
Placebo QD	57.7
Dexlansoprazole MR 30 mg QD	89.3
Dexlansoprazole MR 60 mg QD	86.0

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	Percentage of Days (Median)
Placebo QD	71.7
Dexlansoprazole MR 30 mg QD	98.9
Dexlansoprazole MR 60 mg QD	96.2

Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00321737)
Timeframe: 6 months

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method

Intervention	Percentage of Subjects (Number)
Placebo QD	14.3
Dexlansoprazole MR 30 mg QD	66.4
Dexlansoprazole MR 60 mg QD	66.4

Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00321737)
Timeframe: 6 months

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.

Intervention	Percentage of Subjects (Number)
Placebo QD	27.2
Dexlansoprazole MR 30 mg QD	74.9
Dexlansoprazole MR 60 mg QD	82.5

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked (NCT00255151)
Timeframe: 6 months

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.

Intervention	Percentage of Days (Mean)
Placebo QD	29.5
Dexlansoprazole MR 60 mg QD	79.7
Dexlansoprazole MR 90 mg QD	79.2

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00255151)
Timeframe: 6 months

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.

Intervention	Percentage of Days (Median)
Placebo QD	19.2
Dexlansoprazole MR 60 mg QD	95.8
Dexlansoprazole MR 90 mg QD	94.4

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255151)
Timeframe: 6 months

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.

Intervention	Percentage of Days (Mean)
Placebo QD	48.3
Dexlansoprazole MR 60 mg QD	87.1
Dexlansoprazole MR 90 mg QD	85.4

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255151)
Timeframe: 6 months

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	Percentage of Days (Median)
Placebo QD	50.0
Dexlansoprazole MR 60 mg QD	98.3
Dexlansoprazole MR 90 mg QD	97.1

Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00255151)
Timeframe: 6 months

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method

Intervention	Percentage of Subjects (Number)
Placebo QD	14.3
Dexlansoprazole MR 60 mg QD	66.4
Dexlansoprazole MR 90 mg QD	64.5

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.

Intervention	Percentage of Subjects (Number)
Placebo QD	25.7
Dexlansoprazole MR 60 mg QD	86.6
Dexlansoprazole MR 90 mg QD	82.1

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked (NCT00255164)
Timeframe: 6 months

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.

Intervention	Percentage of Days (Mean)
Placebo QD	29.5
Dexlansoprazole MR 60 mg QD	79.7
Dexlansoprazole MR 90 mg QD	79.2

The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00255164)
Timeframe: 6 months

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.

Intervention	Percentage of Days (Median)
Placebo QD	19.2
Dexlansoprazole MR 60 mg QD	95.8
Dexlansoprazole MR 90 mg QD	94.4

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.

Intervention	Percentage of Days (Mean)
Placebo QD	48.3
Dexlansoprazole MR 60 mg QD	87.1
Dexlansoprazole MR 90 mg QD	85.4

The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.

Intervention	Percentage of Days (Median)
Placebo QD	50.0
Dexlansoprazole MR 60 mg QD	98.3
Dexlansoprazole MR 90 mg QD	97.1

Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00255164)
Timeframe: 6 months

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method

Intervention	Percentage of Subjects (Number)
Placebo QD	14.3
Dexlansoprazole MR 60 mg QD	66.4
Dexlansoprazole MR 90 mg QD	64.5

Number of Participants With Improvement of Espohageal Eosinophilia

Intervention	Percentage of Subjects (Number)
Placebo QD	25.7
Dexlansoprazole MR 60 mg QD	86.6
Dexlansoprazole MR 90 mg QD	82.1

Repeat endoscopy was undertaken using the Olympus P160 endoscope (by RD) at 3 months of treatment. (NCT00638456)
Timeframe: 3 Months

Symptom Score

Intervention	Participants (Count of Participants)
Oral Viscous Budesonide Plus Prevacid	13
Placebo Plus Prevacid	0

"Total score was based on the following symptoms:~Heartburn/regurgitation Abdominal pain Nausea/vomiting Anorexia/early satiety Dysphagia Symptom induced nocturnal wakening Gastrointestinal bleeding~Each symptom could score 0-2 for a maximum score for 14 points. The lower the score the milder the symptoms and the higher the score the more severe symptoms." (NCT00638456)
Timeframe: Baseline and 3 Months

Upper Gastrointestinal Endoscopy Score

Intervention	units on a scale (Mean)
	Baseline	3 months
Oral Viscous Budesonide Plus Prevacid	3.5	1.2
Placebo Plus Prevacid	2.7	1.8

"Endoscopy scoring tool took into account the following categories:~Mucosal pallor/reduced vasculature Linear furrows/mucosal thickening White plaques Concentric rings/stricture Friability/tissue-paper mucosa Histology scoring tools Epithelial histology score Peak eosinophil count~Each category could score 0-3 for a total maximum score of 15. The higher the score the worse the disease." (NCT00638456)
Timeframe: Baseline and 3 Months

Eosinophil Count

Intervention	units on a scale (Mean)
	Baseline	3 months
Oral Viscous Budesonide Plus Prevacid	4.6	1.5
Placebo Plus Prevacid	7.8	5.4

Eosinophils/high powered field(hpf) in the mid esophagus will be measured after 12 weeks of therapy. (NCT01458418)
Timeframe: 12 weeks

Apparent Volume of Distribution (Vz/F) Pharmacokinetic Parameter.

Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz. (NCT00847210)
Timeframe: After 7 days of dosing.

AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter.

AUC(0-24) is measure of Area Under the Curve over the dosing interval (tau) (AUC(0-tau]), where tau is the length of the dosing interval - 24 hours in this study). (NCT00847210)
Timeframe: After 7 days of dosing.

AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration Pharmacokinetic Parameter.

Area Under the Plasma Concentration Versus Time Curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]). (NCT00847210)
Timeframe: After 7 days of dosing.

Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter.

Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. (NCT00847210)
Timeframe: After 7 days of dosing.

Oral Clearance (CL/F) Pharmacokinetic Parameter.

CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr. (NCT00847210)
Timeframe: After 7 days of dosing.

Terminal Elimination Rate Constant (λz) Pharmacokinetic Parameter.

Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body. (NCT00847210)
Timeframe: After 7 days of dosing.

Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter.

Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. (NCT00847210)
Timeframe: After 7 days of dosing.

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter

Tmax: Time to reach the Maximum Plasma Concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 7. (NCT00847210)
Timeframe: After 7 days of dosing.

Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.

number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment

The Median Survival From the Time of Diagnosis.

The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months

Intervention	L (Mean)
Dexlansoprazole MR 30 mg QD	28.90
Dexlansoprazole MR 60 mg QD	58.50

Intervention	ng*hr/mL/mg (Mean)
Dexlansoprazole MR 30 mg QD	2886.26
Dexlansoprazole MR 60 mg QD	5119.81

Intervention	ng*hr/mL/mg (Mean)
Dexlansoprazole MR 30 mg QD	2842.32
Dexlansoprazole MR 60 mg QD	5113.72

Intervention	ng/mL (Mean)
Dexlansoprazole MR 30 mg QD	691
Dexlansoprazole MR 60 mg QD	1136

Intervention	liter/hr (Mean)
Dexlansoprazole MR 30 mg QD	12.81
Dexlansoprazole MR 60 mg QD	15.29

Intervention	1/hr (Mean)
Dexlansoprazole MR 30 mg QD	0.5264
Dexlansoprazole MR 60 mg QD	0.3404

Intervention	hours (Mean)
Dexlansoprazole MR 30 mg QD	1.66
Dexlansoprazole MR 60 mg QD	2.59

Intervention	hours (Mean)
Dexlansoprazole MR 30 mg QD	4.65
Dexlansoprazole MR 60 mg QD	3.31

Article	Year
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2023, Volume: 42, Issue:4 Topics: Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Randomized Contro	2023
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. Alimentary pharmacology & therapeutics, 2009, Sep-15, Volume: 30, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomep	2009
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis. European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazo	2010
Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Drug Interactions; Esophagitis; Gastroesop	2010
Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. Drugs, 2010, Aug-20, Volume: 70, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansopra	2010
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system. Clinical therapeutics, 2010, Volume: 32, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Delayed-Action Preparations; Dexlansoprazole; Esop	2010
Dexlansoprazole MR: a review. Annals of medicine, 2011, Volume: 43, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Dexlansoprazole; Esophagitis;	2011
Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert review of gastroenterology & hepatology, 2011, Volume: 5, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansopra	2011
Gastroesophageal reflux disease: new treatments. Reviews in gastroenterological disorders, 2002, Volume: 2, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esomeprazol	2002
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship,	2003
The impact of gastroesophageal reflux disease on quality of life. Surgical endoscopy, 2003, Volume: 17, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Combined Modality Therapy; Cross-Over St	2003
Intravenous lansoprazole: in erosive oesophagitis. Drugs, 2004, Volume: 64, Issue:18 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Clinical Trials as	2004
Effectiveness of proton pump inhibitors: beyond cost. Reviews in gastroenterological disorders, 2004, Volume: 4 Suppl 4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph	2004
Treatment of gastroesophageal reflux disease. Jornal de pediatria, 2006, Volume: 82, Issue:5 Suppl Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre	2006
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clinical therapeutics, 1993, Volume: 15 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastr	1993
Lansoprazole: a proton pump inhibitor. The Annals of pharmacotherapy, 1996, Volume: 30, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans;	1996
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs, 1997, Volume: 54, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases;	1997
Proton-pump inhibitors for gastric acid-related disease. Cleveland Clinic journal of medicine, 1998, Volume: 65, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter	1998
Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Humans; Lansoprazole; Omepr	2001
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. International journal of clinical practice, 2002, Volume: 56, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym	2002
Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs, 2002, Volume: 62, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophagitis; H	2002

Article	Year
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Alimentary pharmacology & therapeutics, 2013, Volume: 37, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index	2013
High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. Journal of pediatric gastroenterology and nutrition, 2014, Volume: 59, Issue:5 Topics: Adolescent; Anti-Ulcer Agents; Body Mass Index; Child; Child, Preschool; Endoscopy; Esophagitis; Eso	2014
A case of a slightly symptomatic exfoliative oesophagitis. BMJ case reports, 2015, Aug-14, Volume: 2015 Topics: Aged; Antithrombins; Coronary Vessels; Dabigatran; Drug Therapy, Combination; Embolism; Esophagitis;	2015
Association of laryngopharyngeal manifestations and gastroesophageal reflux. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2009, Volume: 266, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Endoscopy, Digestive System; Esophagitis; Fema	2009
Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. Journal of clinical gastroenterology, 2010, Volume: 44, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen	2010
[Eosinophilic esophagitis: report of three cases]. Revista medica de Chile, 2009, Volume: 137, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Adolescent; Child; Cyclopropanes; Eosinophilia; E	2009
Dexlansoprazole for the treatment of esophagitis and GERD. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Child; Clinical Trials as Topic;	2010
Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. The American journal of gastroenterology, 2011, Volume: 106, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dexlansoprazole; Esophagitis; Female; Gastric	2011
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. Journal of gastroenterology, 2003, Volume: 38, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; He	2003
Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice. Journal of pediatric surgery, 2004, Volume: 39, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Child; Cimetidine; Diagnosis, Differential; Enzyme	2004
Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. The American journal of gastroenterology, 2004, Volume: 99, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Enzyme Inhibitors; Esomeprazole; Esophagitis;	2004
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary pharmacology & therapeutics, 2005, Jan-15, Volume: 21, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Enterochromaffin-	2005
Simultaneous herpetic and candidal esophagitis in an immunocompetent teenager. Journal of pediatric gastroenterology and nutrition, 2005, Volume: 40, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acyclovir; Adolescent; Antifungal Agents; Antiviral Agents;	2005
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. Digestive diseases and sciences, 2006, Volume: 51, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch	2006
Pill esophagitis caused by telithromycin: a case report. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2006, Volume: 17, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Endoscopy,	2006
Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2007, Volume: 20, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Esophageal Motility Disorders; Eso	2007
Long-term proton pump inhibitor use in children: a retrospective review of safety. Digestive diseases and sciences, 2008, Volume: 53, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Hum	2008
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta dermato-venereologica, 2008, Volume: 88, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans	2008
Second proton-pump inhibitor marketed. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1995, Aug-01, Volume: 52, Issue:15 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lan	1995
Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole. The British journal of dermatology, 1999, Volume: 141, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dermatitis, Exfoliative; Drug Erup	1999
Pill-induced esophagitis caused by lansoprazole. Journal of gastroenterology, 2001, Volume: 36, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagitis; Female; Humans; Lans	2001
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit	2002

lansoprazole and Esophagitis

Research Excerpts

Research

Studies (77)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

Healing Phase: Percentage of 24-hour Heartburn-free Days

Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2

Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8

Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2

Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8

Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3

Maintenance Phase: Percentage of 24-hour Heartburn-free Days

Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24

Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method

Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean

Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median

Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean

Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.

Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analyses.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.

Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.

Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method

Number of Participants With Improvement of Espohageal Eosinophilia

Symptom Score

Upper Gastrointestinal Endoscopy Score

Eosinophil Count

Apparent Volume of Distribution (Vz/F) Pharmacokinetic Parameter.

AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose Pharmacokinetic Parameter.

AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration Pharmacokinetic Parameter.

Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter.

Oral Clearance (CL/F) Pharmacokinetic Parameter.

Terminal Elimination Rate Constant (λz) Pharmacokinetic Parameter.

Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter.

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter

Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.

The Median Survival From the Time of Diagnosis.

Reviews

Trials

Other Studies